P/E ratio for Palatin Technologies (PTN)

P/E ratio history for Palatin Technologies from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
MediciNova MNOV	-8.00	2,423.17%	🇺🇸 USA
GlycoMimetics GLYC	-0.4923	55.27%	🇺🇸 USA
Neurocrine Biosciences NBIX	63.8	-20,214.58%	🇺🇸 USA
ANI Pharmaceuticals ANIP	-119	37,385.22%	🇺🇸 USA
Ligand Pharmaceuticals LGND	74.2	-23,513.70%	🇺🇸 USA
Dicerna Pharmaceuticals DRNA	N/A	N/A	🇺🇸 USA
Johnson & Johnson JNJ	11.0	-3,581.95%	🇺🇸 USA
Ardelyx ARDX	-42.7	13,356.94%	🇺🇸 USA
AstraZeneca AZN	32.4	-10,310.27%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.